157 related articles for article (PubMed ID: 30587547)
1. An Epithelial-to-Mesenchymal Transcriptional Switch Triggers Evolution of Pulmonary Sarcomatoid Carcinoma (PSC) and Identifies Dasatinib as New Therapeutic Option.
Manzotti G; Torricelli F; Benedetta D; Lococo F; Sancisi V; Rossi G; Piana S; Ciarrocchi A
Clin Cancer Res; 2019 Apr; 25(7):2348-2360. PubMed ID: 30587547
[TBL] [Abstract][Full Text] [Related]
2. The EMT transcription factor, Twist1, as a novel therapeutic target for pulmonary sarcomatoid carcinomas.
Liu T; Zhao X; Zheng X; Zheng Y; Dong X; Zhao N; Liao S; Sun B
Int J Oncol; 2020 Mar; 56(3):750-760. PubMed ID: 32124963
[TBL] [Abstract][Full Text] [Related]
3. Transcriptome profiling reveals novel gene expression signatures and regulating transcription factors of TGFβ-induced epithelial-to-mesenchymal transition.
Du L; Yamamoto S; Burnette BL; Huang D; Gao K; Jamshidi N; Kuo MD
Cancer Med; 2016 Aug; 5(8):1962-72. PubMed ID: 27318801
[TBL] [Abstract][Full Text] [Related]
4. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
Sesumi Y; Suda K; Mizuuchi H; Kobayashi Y; Sato K; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2017 Feb; 104():85-90. PubMed ID: 28213007
[TBL] [Abstract][Full Text] [Related]
5. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
He Y; Xie H; Yu P; Jiang S; Wei L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
[TBL] [Abstract][Full Text] [Related]
6. Mechanism of c-Met and EGFR tyrosine kinase inhibitor resistance through epithelial mesenchymal transition in non-small cell lung cancer.
Rastogi I; Rajanna S; Webb A; Chhabra G; Foster B; Webb B; Puri N
Biochem Biophys Res Commun; 2016 Sep; 477(4):937-944. PubMed ID: 27396618
[TBL] [Abstract][Full Text] [Related]
7. Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer.
Ferrarotto R; Goonatilake R; Yoo SY; Tong P; Giri U; Peng S; Minna J; Girard L; Wang Y; Wang L; Li L; Diao L; Peng DH; Gibbons DL; Glisson BS; Heymach JV; Wang J; Byers LA; Johnson FM
Clin Cancer Res; 2016 Apr; 22(7):1674-1686. PubMed ID: 26597303
[TBL] [Abstract][Full Text] [Related]
8. Synaptotagmin 7 in twist-related protein 1-mediated epithelial - Mesenchymal transition of non-small cell lung cancer.
Liu X; Li C; Yang Y; Liu X; Li R; Zhang M; Yin Y; Qu Y
EBioMedicine; 2019 Aug; 46():42-53. PubMed ID: 31395502
[TBL] [Abstract][Full Text] [Related]
9. A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples.
Pelosi G; Melotti F; Cavazza A; Rossi G; Maisonneuve P; Graziano P; Barbareschi M; Nakatani Y; Papotti M
Anticancer Res; 2012 Apr; 32(4):1463-73. PubMed ID: 22493387
[TBL] [Abstract][Full Text] [Related]
10. Synergistic action of master transcription factors controls epithelial-to-mesenchymal transition.
Chang H; Liu Y; Xue M; Liu H; Du S; Zhang L; Wang P
Nucleic Acids Res; 2016 Apr; 44(6):2514-27. PubMed ID: 26926107
[TBL] [Abstract][Full Text] [Related]
11. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
12. Activation of histamine H4 receptors decreases epithelial-to-mesenchymal transition progress by inhibiting transforming growth factor-β1 signalling pathway in non-small cell lung cancer.
Cai WK; Hu J; Li T; Meng JR; Ma X; Yin SJ; Zhao CH; He GH; Xu GL
Eur J Cancer; 2014 Apr; 50(6):1195-206. PubMed ID: 24447834
[TBL] [Abstract][Full Text] [Related]
13. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
14. YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib.
Garmendia I; Pajares MJ; Hermida-Prado F; Ajona D; Bértolo C; Sainz C; Lavín A; Remírez AB; Valencia K; Moreno H; Ferrer I; Behrens C; Cuadrado M; Paz-Ares L; Bustelo XR; Gil-Bazo I; Alameda D; Lecanda F; Calvo A; Felip E; Sánchez-Céspedes M; Wistuba II; Granda-Diaz R; Rodrigo JP; García-Pedrero JM; Pio R; Montuenga LM; Agorreta J
Am J Respir Crit Care Med; 2019 Oct; 200(7):888-899. PubMed ID: 31166114
[No Abstract] [Full Text] [Related]
15. Integrin-linked kinase pathway in heterogeneous pulmonary sarcomatoid carcinoma.
Shimizu S; Sakai K; Chikugo T; Satou T; Shiraishi N; Mitsudomi T; Nishio K
Oncol Lett; 2021 Apr; 21(4):320. PubMed ID: 33692852
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Soucheray M; Capelletti M; Pulido I; Kuang Y; Paweletz CP; Becker JH; Kikuchi E; Xu C; Patel TB; Al-Shahrour F; Carretero J; Wong KK; Jänne PA; Shapiro GI; Shimamura T
Cancer Res; 2015 Oct; 75(20):4372-83. PubMed ID: 26282169
[TBL] [Abstract][Full Text] [Related]
17. OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Qi XK; Han HQ; Zhang HJ; Xu M; Li L; Chen L; Xiang T; Feng QS; Kang T; Qian CN; Cai MY; Tao Q; Zeng YX; Feng L
Theranostics; 2018; 8(8):2202-2216. PubMed ID: 29721073
[No Abstract] [Full Text] [Related]
18. MiR-145 and miR-203 represses TGF-β-induced epithelial-mesenchymal transition and invasion by inhibiting SMAD3 in non-small cell lung cancer cells.
Hu H; Xu Z; Li C; Xu C; Lei Z; Zhang HT; Zhao J
Lung Cancer; 2016 Jul; 97():87-94. PubMed ID: 27237033
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of SATB2 is critical for induction of epithelial-to-mesenchymal transition and invasion of NSCLC cells.
Kucuksayan H; Ozes ON; Akca H
Lung Cancer; 2016 Aug; 98():122-129. PubMed ID: 27393518
[TBL] [Abstract][Full Text] [Related]
20. Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma.
Lococo F; Gandolfi G; Rossi G; Pinto C; Rapicetta C; Cavazza A; Cesario A; Galeone C; Paci M; Ciarrocchi A
J Thorac Oncol; 2016 Aug; 11(8):1282-1292. PubMed ID: 27156442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
